Editing Pfizer (section)

====2014 Illegal marketing of Rapamune settlement====
A "whistleblower suit" was filed in 2005 against [[Wyeth]], which was acquired by Pfizer in 2009, alleging that the company illegally marketed [[sirolimus]] (Rapamune) for [[off-label use]]s, targeted specific doctors and medical facilities to increase sales of Rapamune, tried to get transplant patients to change from their transplant drugs to Rapamune, and specifically targeted [[African-Americans]]. According to the whistleblowers, Wyeth also provided doctors and hospitals that prescribed the drug with kickbacks such as grants, donations, and other money.<ref>{{Cite magazine |url=https://www.fiercepharma.com/pharma/congress-joins-probe-into-wyeth-s-rapamune-marketing |title=Congress joins probe into Wyeth's Rapamune marketing |first=Tracy |last=Staton |magazine=Fierce Pharma |date=June 14, 2010}}</ref> In 2013, the company pleaded guilty to criminal mis-branding violations under the [[Federal Food, Drug, and Cosmetic Act]]. By August 2014, it had paid $491{{nbsp}}million in civil and criminal penalties related to Rapamune.<ref>{{Cite magazine |url=https://www.fiercepharma.com/regulatory/pfizer-settles-more-off-label-marketing-cases-tied-to-rapamune |title=Pfizer settles more off-label marketing cases tied to Rapamune |first=Eric |last=Palmer |magazine=Fierce Pharma |date=June 14, 2010}}</ref>